Tianjin Lisheng Pharmaceutical Co.,Ltd.

SZSE:002393 Voorraadrapport

Marktkapitalisatie: CN¥4.3b

Tianjin Lisheng PharmaceuticalLtd Inkomsten in het verleden

Verleden criteriumcontroles 2/6

Tianjin Lisheng PharmaceuticalLtd has been growing earnings at an average annual rate of 22.3%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 4.8% per year. Tianjin Lisheng PharmaceuticalLtd's return on equity is 3.7%, and it has net margins of 14.9%.

Belangrijke informatie

22.3%

Groei van de winst

22.2%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie10.9%
Inkomstengroei-4.8%
Rendement op eigen vermogen3.7%
Nettomarge14.9%
Laatste winstupdate30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

These 4 Measures Indicate That Tianjin Lisheng PharmaceuticalLtd (SZSE:002393) Is Using Debt Safely

Sep 28
These 4 Measures Indicate That Tianjin Lisheng PharmaceuticalLtd (SZSE:002393) Is Using Debt Safely

Tianjin Lisheng PharmaceuticalLtd (SZSE:002393) Strong Profits May Be Masking Some Underlying Issues

Mar 28
Tianjin Lisheng PharmaceuticalLtd (SZSE:002393) Strong Profits May Be Masking Some Underlying Issues

Opbrengsten en kosten

Hoe Tianjin Lisheng PharmaceuticalLtd geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

SZSE:002393 Opbrengsten, kosten en inkomsten (CNY Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Sep 241,265188453119
30 Jun 241,24037444891
31 Mar 241,182374425103
31 Dec 231,153362429102
30 Sep 231,15632444191
30 Jun 231,189112466103
31 Mar 231,17698467100
01 Jan 231,14794449102
30 Sep 221,158137481111
30 Jun 221,119133469107
31 Mar 221,071128450101
01 Jan 221,092122466101
30 Sep 211,0612744894
30 Jun 211,1141348293
31 Mar 211,1361051078
31 Dec 201,141954773
30 Sep 201,32113364382
30 Jun 201,37415668690
31 Mar 201,513178773102
31 Dec 191,615188813120
30 Sep 191,61321583975
30 Jun 191,58920583874
31 Mar 191,54418879887
31 Dec 181,50418576992
30 Sep 181,366122707129
30 Jun 181,273107564188
31 Mar 181,138117479144
01 Jan 181,029117420101
30 Sep 1797513734885
30 Jun 179151253940
31 Mar 178961143860
31 Dec 168471163500
30 Sep 16792743270
30 Jun 16769773040
31 Mar 167791102950
31 Dec 157751142910
30 Sep 157621043010
30 Jun 157591043070
31 Mar 15725753010
31 Dec 14774933230
30 Sep 148511293370
30 Jun 149251783450
31 Mar 141,0162523650
31 Dec 131,0442933510

Kwaliteitswinsten: 002393 has high quality earnings.

Groeiende winstmarge: 002393's current net profit margins (14.9%) are lower than last year (28%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: 002393's earnings have grown significantly by 22.3% per year over the past 5 years.

Versnelling van de groei: 002393's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Winst versus industrie: 002393 had negative earnings growth (-41.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.2%).

Rendement op eigen vermogen

Hoge ROE: 002393's Return on Equity (3.7%) is considered low.

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden

7D

1Y

7D

1Y

7D

1Y